While you may have been distracted by Apple’s new product releases and interesting operating system enhancements, the company ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 Filing ...

Curis, Inc. ( NASDAQ: CRIS) Cantor Global Healthcare Conference 2025 September 5, 2025 9:45 AM EDT ...

H.C. Wainwright 27th Annual Global Investment Conference September 10, 2025 10:00 AM EDT Good afternoon. I'm Jim Dentzer, the CEO of Curis. Thank you for taking time today to learn more about us. Over ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1Filing based on four Phase 3 studies that met all primary and co-primary endpoints. Th ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor.1 ...

Background: Consent forms have become too long and often do little to help people understand the risk elements of their participation in research, instead focusing on risk reduction for research ...